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Background: Subcutaneous peginterferon beta-1a provided clinical benefits at Year 1 (placebo-controlled period)
of the 2-Year Phase 3 ADVANCE study in relapsing-remitting multiple sclerosis (RRMS). Here we report the effect of
peginterferon beta-1a on brain magnetic resonance imaging (MRI) lesions, and no evidence of disease activity (NEDA;
absence of clinical [relapses and 12-week confirmed disability progression] and MRI [gadolinium-enhancing, and new
or newly-enlarging T2 hyperintense lesions] disease activity) during Year 1.
Methods: RRMS patients (18–65 years; Expanded Disability Status Scale score ≤5) were randomized to double-blind
placebo or peginterferon beta-1a 125 μg every 2 or 4 weeks. Sensitivity analyses of last observation carried forward and
composite disease activity (using minimal MRI allowance definitions) were conducted.
Results: 1512 patients were randomized and dosed (placebo n = 500; peginterferon beta-1a every 2 [n = 512] or
4 [n = 500] weeks). Every 2 week dosing significantly reduced, versus placebo and every 4 week dosing, the number
of new or newly-enlarging T2 hyperintense lesions at Weeks 24 (by 61% and 51%, respectively) and 48 (secondary
endpoint; by 67% and 54%, respectively); all p < 0.0001. Every 2 week dosing also provided significant reductions
versus placebo and every 4 week dosing in the number of new T1 hypointense, gadolinium-enhancing, and new
active (gadolinium-enhancing plus non-enhancing new T2) lesions (all p < 0.0001), as well as the volume of T2
and T1 lesions (p < 0.05) at Weeks 24 and 48. Significantly more patients dosed every 2 weeks had NEDA versus
placebo and every 4 weeks (all p < 0.01) from baseline to Week 48 (33.9% versus 15.1% and 21.5%, respectively
[odds ratios, ORs: 2.89 and 1.87]), from baseline to Week 24 (41.0% versus 21.9% and 30.7%, [ORs: 2.47 and 1.57]) and
from Week 24 to Week 48 (60.2% versus 28.9% and 36.6%, [ORs: 3.71 and 2.62]). Consistent results were seen when
allowing for minimal MRI activity.
Conclusion: During Year 1 of ADVANCE, significantly more RRMS patients receiving peginterferon beta-1a every
2 weeks had NEDA, and early and sustained improvements in all MRI endpoints, versus placebo and every 4 week
dosing. NEDA sensitivity analyses align with switch strategies in clinical practice settings and provide insight into future
responders/non-responders.
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Subcutaneous (SC) peginterferon beta-1a, a pegylated
form of interferon (IFN) beta-1a, is a new treatment for
relapsing multiple sclerosis (MS) [1-3]. Pegylation (modifi-
cation via attachment of polyethylene glycol [PEG] mole-
cules), has been used to increase half-life and reduce the
immunogenicity of certain drugs with either increased
or sustained efficacy [4-9]. Results from the first year
(placebo-controlled period prior to cross-over onto active
drug) of the 2-year pivotal Phase 3, multicenter, random-
ized ADVANCE study in patients with relapsing-remitting
MS (RRMS) showed that peginterferon beta-1a (125 μg
SC) administered every 2 or 4 weeks significantly im-
proved clinical endpoints, with a reduction in annualized
relapse rate (primary endpoint), and risk of relapse and
12-week confirmed disability progression (both secondary
endpoints), and several MRI-related endpoints versus
placebo, with a safety profile reflecting established IFN
beta-1a therapies [10]. Furthermore, every 2 week dos-
ing provided numerically greater reductions relative to
placebo versus every 4 week dosing across relapse and
all MRI endpoints [10].
Magnetic resonance imaging (MRI) of lesions in the
brain is an important tool for monitoring MS disease
activity and progression [11,12], providing a sensitive
measure of the effects of treatment on focal inflammatory
activity in the central nervous system [13], which initiates
the demyelination and axonal damage associated with MS
disease progression [14,15]. Lesions detected on MRI
scans have been shown to correlate with MS prognosis
[16-18]; thus early reduction in MRI lesions is an import-
ant treatment goal [12].
With the development of effective biological therapies,
no evidence of disease activity (NEDA; absence of clinical
[defined as no relapses and no onset of 12-week confirmed
disability progression] and MRI [no gadolinium-enhancing
lesions and no new or newly-enlarging T2 hyperintense le-
sions] disease activity) is now achievable in many patients
with RRMS [19]. As treatments have improved, annualized
relapse rates recorded in clinical studies have decreased to
the point where there is a need to consider alternative
endpoints to evaluate new treatments for RRMS [20].
NEDA has been proposed for use as an endpoint in MS
studies [20]. It has been evaluated in several MS studies to
date [13,19,21,22], with some variation in its definition to
allow for minimal MRI activity [23]. Although complete
NEDA would be the ideal treatment aspiration, for many
physicians, local guidelines and/or switch recommenda-
tions apply (e.g. two or more new or newly-enlarging
T2-lesions or even a clinical relapse with incomplete re-
mission before escalation is recommended) [24].
The objectives of the present analyses were to explore
the effect of peginterferon beta-1a every 2 and 4 weeks
on MS disease activity as measured by brain MRI lesionsduring Year 1 of the ADVANCE study versus placebo (at
Week 48 ([Year 1], as previously reported [10], and at
the earlier time point of Week 24), with presentation of
new post-hoc statistical analyses for every 2 week versus
every 4 week dose regimen comparisons at these time
points, and to determine the effect of peginterferon
beta-1a on the combined endpoint of NEDA via post-
hoc investigations of Year 1 data (looking at a range of
time-scales to evaluate timing of NEDA impact: baseline
to Week 48, baseline to Week 24, and Week 24 to Week
48). Sensitivity analyses of disease activity were also
carried out to include an allowance for patients who did
not undergo all MRI measures during the study, but had
no evidence of disease activity on any recorded assessment
(last observation carried forward [LOCF] approach), and
using alternative definitions that mimic thresholds used in
clinical practice to guide decision-making on treatment
continuation due to efficacy, or treatment switch due to
inadequate efficacy (no clinical activity with minimal MRI
activity).
Methods
Study design and participants
We conducted a randomized, multicenter (at 183 sites in
26 countries), double-blind, placebo-controlled, parallel
group Phase 3 study of peginterferon beta-1a in patients
with RRMS [10]. Key eligibility criteria were diagnosis of
relapsing MS as defined by the McDonald criteria [25], an
age of 18–65 years, a score of 0–5 on the Expanded Dis-
ability Status Scale (EDSS [26]), and at least two clinically
documented relapses in the previous three years, with
at least one of these relapses having occurred within
12 months prior to randomization. Key exclusion criteria
were progressive forms of MS, pre-specified laboratory ab-
normalities, and prior interferon beta treatment for MS
exceeding four weeks or discontinuation less than six
months prior to baseline. The protocol was approved by
each site’s institutional review board or ethics committee
(a list of ethics committees for participating sites is pro-
vided in Additional file 1). The ethics committee at Johns
Hopkins University (the site of the Principal Investigator)
was Johns Hopkins Medicine Institutional Review Board,
Baltimore, MD, USA. The study was conducted according
to the International Conference on Harmonization Guide-
lines for Good Clinical Practice and the Declaration of
Helsinki. Every patient provided written informed consent
prior to study entry.
Study procedures and endpoints
The methods of the ADVANCE study have been published
previously [10]. Here, we focus on information specific to
the analyses presented.
Patients were randomly assigned in a 1:1:1 ratio to re-
ceive SC injections of placebo (Year 1 only), peginterferon
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beta-1a 125 μg every 4 weeks. Patients received either
peginterferon beta-1a or placebo every 2 weeks to main-
tain the blind; those randomized to the peginterferon
beta-1a every 4 week group received alternate injections
of placebo and peginterferon beta-1a every 4 weeks. Par-
ticipants randomized to receive peginterferon beta-1a at
beginning of study, and those re-randomized to active
drug after first year, underwent dose escalation over the
first four weeks of the treatment to mitigate influenza-like
symptoms (starting dose 63 μg; 94 μg at Week 2; target
dose 125 μg at Week 4 and thereafter) [10]. The current
analysis evaluates the effects of receiving peginterferon
beta-1a vs. placebo in Year 1 (baseline to 48 weeks) of the
ADVANCE study. All study management and site
personnel, investigators, and patients were blinded to
treatment assignment including dose escalation. Each
site used separate examining and treating neurologists,
thereby maintaining rater blinding for all treatment
groups.
MRI scans were obtained at screening, and at Weeks
24, and 48, and were evaluated in a blinded manner at
a central MRI reading center (NeuroRx Research, Montreal,
Canada).
The number of new or newly-enlarging T2 hyperin-
tense lesions at Week 48 compared with baseline was a
secondary endpoint of the study. Tertiary MRI endpoints
included the number of new or newly-enlarging T2 hyper-
intense lesions at Week 24, the number of gadolinium-
enhancing (Gd+), new T1 hypointense, and new active
(sum of Gd+ plus non-enhancing new or newly-enlarging
T2 hyperintense) lesions, at Weeks 24 and 48, and the
volume of T2 and T1 hypointense lesions, at Weeks 24
and 48.
Post-hoc NEDA analyses during Year 1 of the
ADVANCE study were carried out and summarized
as data from baseline to Week 48, baseline to Week
24 and Week 24 to Week 48 using the following
definitions: NEDA was defined as absence of both clinical
[no relapses and no onset of 12-week confirmed disability
progression over the interval] and MRI [no Gd+ lesions
and no new or newly-enlarging T2 hyperintense lesions]
disease activity during the respective time periods; MRI-
NEDA only was defined as no Gd+ lesions at Weeks 24
and 48 and no new or newly-enlarging T2 lesions at Week
48 compared with baseline (for data summarized from
baseline to Week 48), no Gd+ lesions at Week 24 and no
new or newly-enlarging T2 lesions at Week 24 compared
with baseline (for data summarized from baseline to Week
24), and no Gd+ at Week 48 and no new or newly-
enlarging T2 lesions at Week 48 compared with Week 24
or the closest previous visit before Week 48 (for data sum-
marized from Week 24 to Week 48); clinical-NEDA only
was defined as no relapses and no onset of 12-weekconfirmed disability progression over the intervals spe-
cified (including 12 weeks confirmation at Week 60).
Sensitivity analyses were also carried out on data from
baseline to Week 48 to include an allowance for patients
with missing measures of MRI disease activity (analysis 1
below) and using definitions with an allowance for min-
imal MRI activity (analyses 2 and 3 below):
 Sensitivity analysis 1: definitions described above
were applied using LOCF (i.e. patients were not
excluded from overall NEDA analyses if they did not
have complete MRI scan data during Year 1, and
were not excluded from MRI-NEDA only analyses if
they only had partial MRI scan data during Year 1;
patients were excluded from MRI-NEDA only
analyses if they were missing all MRI scan data
during Year 1).
 Sensitivity analysis 2: sum of number of new or
newly-enlarging T2 lesions at Week 48 compared
with baseline and Gd+ lesions at both Week 24 and
Week 48 ≤2.
 Sensitivity analysis 3: ≤1 new or newly-enlarging T2
lesion at Week 48 compared with baseline and no
Gd+ lesions at Weeks 24 and 48.
Statistical analysis
Statistical tests were two-sided. Multiple comparisons
adjustments were performed on the primary and second-
ary endpoints for the study, with an overall type I error
rate of 0.05. All primary and secondary endpoints for the
study were statistically significant for both dose frequen-
cies [10]. However no multiple comparisons adjustments
were performed on tertiary endpoints or post-hoc ana-
lyses, so nominal p-values are reported here for each
endpoint.
MRI results were derived from patients who had any
MRI data (a majority of the overall study intention-to-treat
[ITT] population [randomized patients who received at
least one dose of study treatment]) [10]. Negative binomial
regression was used for analysis of new or newly-enlarging
hyperintense lesions on T2-weighted images (adjusted
for baseline number of T2 lesions) and new active le-
sions (adjusted for baseline number of Gd+ lesions);
multiple logit regression was used for the analysis of
Gd+ and new T1-hypointense lesions (adjusted for
baseline number of respective lesions) [10]. Analysis of
covariance (ANCOVA) was used for analysis of lesion
volumes, adjusted for respective baseline lesion volumes
[10]. Comparisons of active treatment dosing regimens
versus placebo were pre-specified; every 2 week versus
every 4 week comparisons were post-hoc. Post-hoc NEDA
and disease activity sensitivity analyses (no clinical activity
with minimal MRI activity) proportions were calculated
directly based on the definitions using data from all
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calculate odds ratios (ORs) and corresponding p-values.
Results
Patient disposition and baseline characteristics
A total of 1516 patients underwent randomization, of
whom 1512 received at least one dose of study drug and
were included in the ITT population (placebo n = 500;
peginterferon beta-1a every 2 weeks n = 512; peginterferon
beta-1a every 4 weeks n = 500) [10]. Patient demographics
and baseline disease characteristics in the overall study
population were generally well balanced across the treat-
ment groups [10]; data are summarized in Table 1. Pa-
tients included in ADVANCE had mean baseline EDSS
scores of 2.44−2.48; 17% had been treated with any MS
medication prior to study entry, including 7% who used
beta interferons or glatiramer acetate. Compared with the
placebo and peginterferon beta-1a every 4 week groups,
slightly more subjects in the peginterferon beta-1a every
2 week group had no Gd+ lesions at baseline (59%,
59%, and 65%, respectively; Table 1) and mean number
of Gd+ lesions at baseline was also lower in this treat-
ment group (Table 1); as mentioned above, analyses of
Gd+ lesion number were adjusted for baseline Gd+ num-
ber of lesions. The overall study completion rate for Year
1 was 88% (a complete overview of ADVANCE Year 1 pa-
tient disposition has been published previously [10]).
MRI outcomes
Peginterferon beta-1a every 2 weeks significantly reduced
the number of new or newly-enlarging T2 lesions, new T1
hypointense lesions, Gd+ lesions, and new active le-
sions at Weeks 24 and 48, compared with placebo andTable 1 Patient demographics and baseline disease character
Characteristic Placebo
(n = 500)
Age, years 36.3 (9.74)
Gender, % female 72
Time since first MS symptoms, years 6.3 (6.28)
Relapses within the previous 12 months 1.6 (0.67)
EDSS Score 2.44 (1.18)
Number who took any prior MS medicationa, n (%) 86 (17)
No Gd+ lesions, n (%) 296 (59)
Number of T2 lesions 50.6 (35.7)
Number of T1 hypointense lesions 28.1 (29.2)
Number of Gd+ lesions 1.6 (3.81)
Volume of T2 lesions, cm3 10.1 (11.9)
Volume of T1 hypointense lesions, cm3 3.1 (4.80)
MRI results are reported for a slightly smaller number of patients compared with th
presented as mean (standard deviation), unless otherwise stated. aInterferon beta-1
EDSS = Expanded Disability Status Scale; Gd+ = gadolinium-enhancing; MS =multippeginterferon beta-1a every 4 weeks (all p < 0.0001;
Figure 1). Peginterferon beta-1a every 4 weeks signifi-
cantly reduced the number of new or newly-enlarging
T2 lesions (Figure 1) and new active lesions at Weeks
24 and 48, compared with placebo (Additional file 2), and
numerically reduced the number of new T1 hypointense
lesions and Gd+ lesions, although reductions did not
reach statistical significance (Figure 1).
Peginterferon beta-1a every 2 weeks significantly re-
duced the volume of T2 and T1 hypointense lesions at
Weeks 24 and 48, compared with placebo and peginter-
feron beta-1a every 4 weeks (Table 2). Peginterferon beta-
1a every 4 weeks significantly reduced the volume of T2
lesions at Weeks 24 and 48, compared with placebo
(Table 2); no significant reduction in the volume of T1
hypointense lesions was seen versus placebo at Weeks 24
or 48 for every 4 week dosing (Table 2).
Analyses of achieving no evidence of disease activity
Significantly higher proportions of patients receiving
peginterferon beta-1a every 2 and every 4 weeks had
NEDA during each assessment period, compared with
placebo (baseline to Week 48 ORs: 2.89 [p < 0.0001]
and 1.55 [p = 0.0103], respectively; baseline to Week 24
ORs: 2.47 [p < 0.0001] and 1.58 [p = 0.0022], respectively;
Weeks 24–48 ORs: 3.71 [p < 0.001] and 1.42 [p = 0.0127],
respectively; Figure 2). Significantly more patients had
NEDA on every 2 week versus every 4 week dosing
(baseline to Week 48: OR 1.87 [p < 0.0001]; baseline to
Week 24: OR 1.57 [p = 0.0011]; Weeks 24–48: OR 2.62
[p < 0.001]; Figure 2). Less measured disease activity was
observed in Weeks 24–48 than in the first 24 weeks for
the every 2 week dosing group.istics of the ITT population [10]
Peginterferon beta-1a
125 μg every 4 weeks
Peginterferon beta-1a
125 μg every 2 weeks
(n = 500) (n = 512)
36.4 (9.87) 36.9 (9.79)
70 71
6.5 (6.07) 6.9 (6.61)
1.5 (0.62) 1.6 (0.67)
2.48 (1.24) 2.47 (1.26)
85 (17) 89 (17)
297 (59) 334 (65)
51.4 (36.0) 48.7 (36.8)
29.6 (30.8) 27.8 (28.1)
1.8 (5.38) 1.2 (3.44)
11.3 (13.2) 9.8 (11.6)
3.1 (4.76) 3.0 (4.50)
e ITT population (due to the availability of MRI scans to analyze). Data are
a, interferon beta-1b, or glatiramer acetate.
le sclerosis.
Figure 1 (See legend on next page.)
Arnold et al. BMC Neurology  (2014) 14:240 Page 5 of 11
(See figure on previous page.)
Figure 1 Lesion numbers at Weeks 24 and 48. A) New or newly-enlarging T2 lesions aBased on negative binomial regression analysis, adjusted
baseline T2 lesion number. The data for 48 weeks has been published previously [10]. CI = confidence interval. B) New T1 hypointense lesions
compared to baseline bBased on mean number of new lesions only and p value based on multiple logit regression, adjusted for baseline number
of T1 lesions. The data for 48 weeks has been published previously [10]. SE = standard error. C) Gd+ lesions cBased on mean number of lesions
only and p value based on multiple logit regression, adjusted for baseline number of Gd+ lesions. Gd+ = gadolinium-enhancing;
SE = standard error.
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peginterferon beta-1a every 2 and every 4 weeks had
MRI-NEDA during each assessment period, compared
with placebo (baseline to Week 48 ORs: 2.94 [p < 0.0001]
and 1.41 [p = 0.0318], respectively; baseline to Week 24
ORs: 2.44 [p < 0.0001] and 1.46 [p = 0.0078], respectively;
Weeks 24–48 ORs: 4.11 [p < 0.0001] and 1.44 [p = 0.0080],
respectively; Additional file 2). Significantly more patients
had MRI-NEDA on every 2 week versus every 4 week
dosing (baseline to Week 48: OR 2.09 [p < 0.0001]; base-
line to Week 24: OR 1.67 [p = 0.0002]; Weeks 24–48
OR: 2.86 [p < 0.0001]; Additional file 2).
Significantly greater proportions of patients receiving
peginterferon beta-1a every 2 and every 4 weeks had
clinical-NEDA from baseline to Week 48 and from base-
line to Week 24, compared with placebo (baseline to
Week 48 ORs: 1.77 [p < 0.0001] and 1.48 [p = 0.0060],
respectively; baseline to Week 24 ORs: 1.57 [p = 0.0088]
and 1.61 [p = 0.0063], respectively; Additional file 2).
From Weeks 24 to 48, significantly greater proportions
of patients receiving peginterferon beta-1a every 2 weeks
had clinical-NEDA, compared with placebo (OR: 1.75
[p = 0.0070]; every 4 weeks vs. placebo OR: 1.22 [p =
0.3058]; Additional file 2). No significant difference was
seen between every 2 week and every 4 week dosing forTable 2 Lesion volumes at Weeks 24 and 48 compared to bas
Characteristic P
(n
Mean change from baseline in T2 lesion volume, cm3, at 24 weeks 0
P value vs. placebo
P value vs. every 4 weeks -
Mean change from baseline in T2 lesion volume, cm3, at 48 weeks 0
P value vs. placebo
P value vs. every 4 weeks -
Mean change from baseline in TI hypointense lesion volume, cm3,
at 24 weeks
0
P value vs. placebo
P value vs. every 4 weeks -
Mean change from baseline in TI hypointense lesion volume, cm3,
at 48 weeks
0
P value vs. placebo
P value vs. every 4 weeks -proportions of clinical-NEDA patients (baseline to
Week 48: OR 1.20 [p = 0.2367]; baseline to Week 24:
OR 0.98 [p = 0.8947]; Weeks 24–48 OR: 1.44 [p = 0.0898];
Additional file 2).
Results from disease activity sensitivity analyses involv-
ing an allowance for missing MRI scan data, or defined
as no clinical activity with allowances for minimal MRI
activity, were consistent with the primary NEDA ana-
lyses, with higher ORs for peginterferon beta-1a every
2 weeks, favoring this dosing regimen over every 4 weeks
and placebo (Table 3).
Discussion
The MRI outcomes of peginterferon beta-1a observed
here are consistent with the robust benefits on clinical
outcomes after one year of treatment (reductions in risk
of 12-week confirmed disability progression [every 2 and
4 weeks 38%], risk of relapse [every 2 weeks 39%; every
4 weeks 26%], and annualized relapse rate [every 2 weeks
36%; every 4 weeks 28%]), as reported previously for the
Phase 3 ADVANCE study [10]. Peginterferon beta-1a
every 2 weeks provided superior outcomes for MRI
lesion-based endpoints (including numbers of new or
newly-enlarging T2 lesions, new T1 lesions, Gd+




125 μg every 4 weeks
Peginterferon beta-1a
125 μg every 2 weeks
(n = 462) (n = 457)
.34 0.14 −0.22
p = 0.0006 p < 0.0001
- p < 0.0001
.77 0.06 −0.26
p < 0.0001 p < 0.0001
- p < 0.0001
.29 0.31 0.18
p = 0.22 p = 0.0002
- p = 0.014
.54 0.57 0.32
p = 0.18 p < 0.0001
- p = 0.0032
Figure 2 NEDA proportions. A) Baseline to Week 48. B). Baseline to Week 24. C). Weeks 24–48. ORs are shown with 95% confidence
intervals in parentheses. aDefined as absence of both clinical (no relapses and no onset of 12-week confirmed disability progression over
the interval) and MRI (no gadolinium-enhancing lesions and no new or newly-enlarging T2 hyperintense lesions) disease activity; data from
patients with complete MRI results during the time interval were used for analysis of MRI disease activity. NEDA = No evidence of disease
activity; MRI = magnetic resonance imaging; OR = odds ratio.
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placebo and versus peginterferon beta-1a every 4 weeks,
with statistical significance observed at the first brain MRI
scheduled at Week 24 of treatment, and greater reduc-
tions through to Week 48 of the ADVANCE study. Pegin-
terferon beta-1a every 4 weeks also provided superior
results versus placebo at Weeks 24 and 48 for numbers ofnew or newly-enlarging T2 lesions and new active lesions,
and the volume of T2 lesions, but not for numbers of
Gd+ or T1 lesions, nor volume of T1 lesions.
An early decrease in brain inflammation, as shown by
reductions in MRI disease activity, is particularly desirable
in MS, as it may impact on associated injury to myelin
and axons, with consequences for the accumulation of
Table 3 Sensitivity analyses of disease activity at Week 48
Placebo Peginterferon beta-1a every 4 weeks Peginterferon beta-1a every 2 weeks
Sensitivity analysis 1a
NEDA
n/N (%) 89/500 (17.8) 132/500 (26.4) 204/512 (39.8)
OR (95% CI) vs. placebo - 1.66 (1.22, 2.24) 3.06 (2.29, 4.09)
p = 0.0011 p < 0.0001
OR (95% CI) vs. every 4 weeks - - 1.85 (1.42, 2.41)
p < 0.0001
MRI-NEDA only
n/N (%) 91/477 (19.1) 116/463 (25.1) 187/457 (40.9)
OR (95% CI) vs. placebo - 1.42 (1.04, 1.93) 2.94 (2.19, 3.95)
p = 0.0274 p < 0.0001
OR (95% CI) vs. every 4 weeks - - 2.07 (1.56, 2.74)
p < 0.0001
Sensitivity analysis 2b
No clinical activity + minimal MRI activity
n/N (%) 129/483 (26.7) 160/469 (34.1) 251/466 (53.9)
OR (95% CI) vs. placebo - 1.42 (1.08, 1.88) 3.20 (2.44, 4.20)
p = 0.0131 p < 0.0001
OR (95% CI) vs. every 4 weeks - - 2.25 (1.73, 2.94)
p < 0.0001
Minimal MRI activity
n/N (%) 161/476 (33.8) 194/462 (42.0) 295/457 (64.6)
OR (95% CI) vs. placebo - 1.42 (1.09, 1.85) 3.56 (2.72, 4.67)
p = 0.0100 p < 0.0001
OR (95% CI) vs. every 4 weeks - - 2.52 (1.93, 3.28)
p < 0.0001
Sensitivity analysis 3c
No clinical activity + minimal MRI activity
n/N (%) 104/484 (21.5) 135/469 (28.8) 214/466 (45.9)
OR (95% CI) vs. placebo - 1.48 (1.10, 1.98) 3.10 (2.34, 4.12)
p = 0.0096 p < 0.0001
OR (95% CI) vs. every 4 weeks - - 2.10 (1.60, 2.75)
p < 0.0001
Minimal MRI activity
n/N (%) 129/477 (27.0) 158/462 (34.2) 251/457 (54.9)
OR (95% CI) vs. placebo - 1.40 (1.06, 1.85) 3.29 (2.50, 4.32)
p = 0.0175 p < 0.0001
OR (95% CI) vs. every 4 weeks - - 2.34 (1.80, 3.06)
p < 0.0001
aLOCF (i.e. patients were not excluded from NEDA analyses if they had missing MRI scan data during Year 1, and were not excluded from MRI-NEDA only analyses
if they had data from ≥1 MRI scan during Year 1); bDefined as the total number of new or newly-enlarging T2 lesions at Week 48 compared to baseline and the
number of gadolinium-enhancing lesions at both Week 24 and Week 48 ≤2; cDefined as ≤1 new or newly-enlarging T2 lesion at Week 48 compared with baseline
and no gadolinium-enhancing lesions at Weeks 24 and 48. CI = confidence interval; LOCF = last observation carried forward; n/N = patients free from disease
activity/total number of patients analyzed; OR = odds ratio.
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shown to be strong predictors of clinical prognosis for MS
patients [15-18,27,28].
This study also carried out post-hoc analyses of
ADVANCE Year 1 data using composites of clinical
and radiological indicators of disease activity, which
are commonly used as endpoints in MS clinical trials
[29-33]. Efficacy data show that proportions of patients
with NEDA and MRI-NEDA only) were significantly
higher with peginterferon beta-1a every 2 weeks from
baseline to Week 48, from baseline to Week 24 and from
Weeks 24 to 48, versus placebo and peginterferon beta-1a
every 4 weeks. Furthermore, the sensitivity analyses of
disease activity conducted support the robustness of the
results of the primary NEDA analyses, indicating that
the effects of peginterferon beta-1a are sustained when
including an allowance for patients who did not undergo
all MRI measures during the study, but had no evidence
of disease activity on any recorded assessment, and when
applying definitions with allowances for minimal MRI ac-
tivity. These observations are important because brain
MRIs within 12 months of starting a disease-modifying
therapy are a sensitive tool in predicting response to treat-
ment, along with the early identification of patients who
will develop long-term disability progression [15,27,28,34].
MRI allowance is pertinent to current practice, as scans
obtained 6–12 months after starting a new therapy may
include MRI activity occurring before efficacy of a new
therapy is apparent. Of note, fewer lesions were seen in
the present study from Weeks 24–48, versus baseline
to Week 24, and comparative ORs for NEDA and MRI-
NEDA were higher from Week 24 to 48, compared
with baseline to Week 24 and baseline to Week 48.
Therefore, an MRI baseline established 6 months after
treatment initiation may more effectively demonstrate
differences between treatment arms. Further, activity
on MRI may also indicate a need to switch to a treat-
ment with an alternative mode of action, with the aim
of avoiding irreversible clinical neurological disability
[34,35]; however this need may be more appropriately
assessed by establishing a baseline for new disease activity
(e.g. at 24 weeks) thus avoiding switch to potentially less
safe treatments.
NEDA analyses in the ADVANCE study reflect efficacy
levels previously reported in other Phase 3 trials of
agents approved for the treatment of relapsing forms of
MS, however, it is important to consider that direct
comparisons across studies may not be advisable due to
differences between study design, patient populations,
MRI techniques and MRI reading techniques used
across different studies. In the FREEDOMS II study in
RRMS, at Month 24 significantly more patients had
freedom from indicators of new inflammatory activity
(i.e. no gadolinium-enhanced T1 lesions and no new ornewly-enlarged T2 lesions) on fingolimod (0.5 mg 50%;
1.25 mg 63%) compared with those on placebo (26%);
no composites of clinical-NEDA or complete NEDA were
reported in the FREEDOMS II study [36]; although no OR
were reported, the relative differences between placebo
and actives arms are similar to the findings in the present
study.
It is important to compare methods of analysis (e.g.
LOCF or non-LOCF), sensitivity of MRI analyses (e.g.
computerized or visual read of scans) and numbers of
scans when trying to estimate efficacy by endpoints like
NEDA, or FMDA (Freedom from Measured Disease Ac-
tivity), as termed by others, among different treatment
options; it would therefore be optimal to make compari-
sons versus placebo-treated patients and to also compare
OR results, rather than just absolute numbers.
Further analyses will be necessary to determine whether
these early patients who had NEDA in the ADVANCE
study remain NEDA over the longer term (i.e., after
96 weeks). A multicenter, dose-frequency blinded mini-
mum 2-year extension of the ADVANCE study is also
underway (ATTAIN; NCT01332019), which may allow
for the provision of 4-year data.Conclusion
Analyses of MRI outcomes and NEDA, along with efficacy
for single clinical endpoints reported previously [10],
support SC peginterferon beta-1a every 2 weeks as an
effective treatment option for patients with RRMS, with
the benefit of less frequent administration.Additional files
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Additional file 2: Figure S1. Lesion numbers at Weeks 24 and 48.
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